US2021169810A1PendingUtilityA1
Tamper resistant dosage forms
Est. expiryAug 25, 2026(~0.1 yrs left)· nominal 20-yr term from priority
A61K 9/1641A61P 29/02A61K 47/34A61K 9/2086A61K 9/2095A61P 25/00A61K 9/2013A61K 9/2054A61J 3/10A61K 9/2031B29C 35/16B29C 37/0025B29B 7/02B29C 71/00A61K 31/485A61K 45/06A61K 9/28A61K 9/2853A61K 9/2027A61K 9/2072A61K 9/2866A61P 29/00B29K 2105/251A61K 9/209A61K 9/2893B29L 2031/753B29C 43/52A61K 9/0053B29C 2035/046A61P 25/04B29C 43/02A61K 9/2018B29K 2995/0088A61J 3/005B29C 35/045A61K 9/0002B29B 7/88B29C 71/009A61J 3/06B29C 43/003A61K 9/2077B29K 2071/02A61K 47/10B29K 2105/0035A61K 9/284A61K 9/16B29C 2035/1658
79
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Claims
exact text as granted — not AI-modified1 . A process of preparing a solid oral extended release pharmaceutical dosage form, comprising at least the steps of:
(a) combining at least
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000, and
(2) at least one active agent,
to form a composition;
(b) shaping the composition to form an extended release matrix formulation; and (c) curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least about 1 minute.
2 - 169 . (canceled)Join the waitlist — get patent alerts
Track US2021169810A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.